SHIONOGI & CO., LTD.

ViiV Healthcare Files a New Drug Application for the Integrase Inhibitor "Dolutegravir"

Osaka, Japan, December 18, 2012 - Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") today announced that ViiV Healthcare (Head Office: London; Chief Executive Officer: Dr. Dominique Limet) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and Canada for the investigational integrase inhibitor dolutegravir for the treatment of HIV infection in adults and adolescents.

Dolutegravir is an investigational integrase inhibitor for the treatment of HIV, which had been developed by Shionogi-ViiV Healthcare LLC, and currently in development by ViiV Healthcare based on the new agreement between Shionogi and ViiV Healthcare announced in October 2012. Phase III studies had been started since October 2010, and we have already announced that the phase III data required for initial regulatory filings of dolutegravir in adults infected with HIV were in house. This time, ViiV Healthcare announced that it filed an NDA in the US, EU and Canada.

Shionogi is striving to maximize the full potential long-term value of dolutegravir and other integrase inhibitors in the portfolio as a shareholder of ViiV Healthcare.

Forward-looking Statements
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For further information, contact:
Corporate Communications
Shionogi & Co., Ltd.
Osaka Telephone: +81-6-6209-7885 Fax: +81-6-6229-9596
Tokyo Telephone: +81-3-3406-8164 Fax: +81-3-3406-8099